ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
The company does not expect the outcome of this inspection to impact its plans
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
It is a recombinant nanoparticle protein-based vaccine
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
Subscribe To Our Newsletter & Stay Updated
